Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Jun;70(6):727-35.
doi: 10.1001/jamaneurol.2013.1925.

A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies

Michael A Nalls  1 , Raquel Duran, Grisel Lopez, Marzena Kurzawa-Akanbi, Ian G McKeith, Patrick F Chinnery, Christopher M Morris, Jessie Theuns, David Crosiers, Patrick Cras, Sebastiaan Engelborghs, Peter Paul De Deyn, Christine Van Broeckhoven, David M A Mann, Julie Snowden, Stuart Pickering-Brown, Nicola Halliwell, Yvonne Davidson, Linda Gibbons, Jenny Harris, Una-Marie Sheerin, Jose Bras, John Hardy, Lorraine Clark, Karen Marder, Lawrence S Honig, Daniela Berg, Walter Maetzler, Kathrin Brockmann, Thomas Gasser, Fabiana Novellino, Aldo Quattrone, Grazia Annesi, Elvira Valeria De Marco, Ekaterina Rogaeva, Mario Masellis, Sandra E Black, Juan M Bilbao, Tatiana Foroud, Bernardino Ghetti, William C Nichols, Nathan Pankratz, Glenda Halliday, Suzanne Lesage, Stephan Klebe, Alexandra Durr, Charles Duyckaerts, Alexis Brice, Benoit I Giasson, John Q Trojanowski, Howard I Hurtig, Nahid Tayebi, Claudia Landazabal, Melanie A Knight, Margaux Keller, Andrew B Singleton, Tyra G Wolfsberg, Ellen Sidransky
Affiliations
Randomized Controlled Trial

A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies

Michael A Nalls et al. JAMA Neurol. 2013 Jun.

Abstract

Importance: While mutations in glucocerebrosidase (GBA1) are associated with an increased risk for Parkinson disease (PD), it is important to establish whether such mutations are also a common risk factor for other Lewy body disorders.

Objective: To establish whether GBA1 mutations are a risk factor for dementia with Lewy bodies (DLB). DESIGN We compared genotype data on patients and controls from 11 centers. Data concerning demographics, age at onset, disease duration, and clinical and pathological features were collected when available. We conducted pooled analyses using logistic regression to investigate GBA1 mutation carrier status as predicting DLB or PD with dementia status, using common control subjects as a reference group. Random-effects meta-analyses were conducted to account for additional heterogeneity.

Setting: Eleven centers from sites around the world performing genotyping.

Participants: Seven hundred twenty-one cases met diagnostic criteria for DLB and 151 had PD with dementia. We compared these cases with 1962 controls from the same centers matched for age, sex, and ethnicity.

Main outcome measures: Frequency of GBA1 mutations in cases and controls. RESULTS We found a significant association between GBA1 mutation carrier status and DLB, with an odds ratio of 8.28 (95% CI, 4.78-14.88). The odds ratio for PD with dementia was 6.48 (95% CI, 2.53-15.37). The mean age at diagnosis of DLB was earlier in GBA1 mutation carriers than in noncarriers (63.5 vs 68.9 years; P < .001), with higher disease severity scores.

Conclusions and relevance: Mutations in GBA1 are a significant risk factor for DLB. GBA1 mutations likely play an even larger role in the genetic etiology of DLB than in PD, providing insight into the role of glucocerebrosidase in Lewy body disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Crosiers reports receiving travel support from Abbott and Boehringer Ingelheim. Dr Brockmann reports receiving speaker honoraria from Deutsche Gesellschaft für klinische Neurophysiologie, GlaxoSmithKline, and Orion Corporation. Dr Berg reports receiving consultation fees from UCB Schwarz Pharma, Merz, and Novartis; payment for lectures from Teva, GSC, Lundbeck, and UCB Schwarz Pharma; and grant support from Janssen Pharmaceutica, Teva, Michael J. Fox Foundation, the Federal Ministry of Education and Research, Abbott, Boehringer, German Parkinson’s Disease Association, and the Center for Integrative Neurosciences. Dr Gasser reports receiving consultation fees from Cefalon Pharma and Merck-Serono; lecture fees from Valeant Pharma, Merck-Serono, UCB-Pharma, and Boehringer; and grant support from Novartis Pharma, European Union, Helmholtz Association, and the Federal Ministry of Education and Research. Dr Maetzler reports receiving lecture fees from GlaxoSmithKline and grant support from the Robert Bosch Foundation. Dr Masellis reports receiving speaker honoraria from Novartis and EMD Serono, Inc; serving as an associate editor for Current Pharmacogenomics and Personalized Medicine; receiving publishing royalties from Henry Stewart Talks; serving as a consultant for Bioscape Medical Imaging CRO; and receiving research support from the Canadian Institutes of Health Research, Parkinson Society Canada, an Early Researcher Award from the Ministry of Economic Development and Innovation of Ontario, Teva Pharmaceutical Industries Ltd, and the Department of Medicine, Sunnybrook Health Sciences Centre. Dr Black reports receiving contract research funds to the Cognitive Neurology Research and Stroke Research Units from Roche, GlaxoSmithKline, Novartis, Myriad, Pfizer, sanofi-aventis, Boehringer Ingelheim, Lundbeck, Novo Nordisk, and AstraZeneca and honoraria from Janssen-Ortho, Novartis, Lundbeck, Pfizer, Eisai, Myriad, GlaxoSmithKline, Roche, Schering-Plough, Elan, Wyeth, and Bristol-Myers Squibb. Dr Ghetti reports receiving support from Elan and Bayer Schering Pharma AG. Dr Nichols reports receiving support from the National Institute of Neurological Disorders and Stroke, National Institutes of Health (NIH).

Figures

Figure
Figure
Forest plots detailing study analyses. A, Stratification by genotyping method differentiated by depth of screening. B, Stratification by clinically vs pathologically based diagnoses. OR indicates odds ratio.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lwin A, Orvisky E, Goker-Alpan O, LaMarca ME, Sidransky E. Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab. 2004;81(1):70–73. - PubMed
    1. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. N Engl J Med. 2004;351(19):1972–1977. - PubMed
    1. Gan-Or Z, Giladi N, Rozovski U, et al. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology. 2008;70 (24):2277–2283. - PubMed
    1. Mata IF, Samii A, Schneer SH, et al. Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch Neurol. 2008;65(3):379–382. - PMC - PubMed
    1. Mitsui J, Mizuta I, Toyoda A, et al. Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch Neurol. 2009;66(5):571–576. - PubMed

Publication types

Substances

Grants and funding